Coya CEO update: ALS POC shows disease halted 24wks; AD Phase2 data due Q2 2024

Coya Therapeutics, Inc.

COYA 302 in ALS: disease progression halted to week 24 with minimal decline to week 48 on ALSFRS scale in open-label study.
COYA 301 in AD: cognitive function improved or stabilized; Treg function enhanced, cytokines reduced, neuroinflammation decreased.
Pre-IND meeting with FDA for COYA 302 planned fall 2023; IND submission early 2024 with Phase 2 trial to follow.
Academic double-blind Phase 2 trial of low-dose IL-2 in AD (funded by Gates Foundation) top-line data expected Q2 2024.
Appointed immunologist Dr. Guillaume Dorothee to SAB; hired Arun Swaminathan as business development executive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.